GB1458048A - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
GB1458048A
GB1458048A GB5864273A GB5864273A GB1458048A GB 1458048 A GB1458048 A GB 1458048A GB 5864273 A GB5864273 A GB 5864273A GB 5864273 A GB5864273 A GB 5864273A GB 1458048 A GB1458048 A GB 1458048A
Authority
GB
United Kingdom
Prior art keywords
carrier
compositions
dec
pharmaceutical compositions
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5864273A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AFFILIATED MED RES
Original Assignee
AFFILIATED MED RES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US00315836A external-priority patent/US3839346A/en
Application filed by AFFILIATED MED RES filed Critical AFFILIATED MED RES
Publication of GB1458048A publication Critical patent/GB1458048A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1458048 Pharmaceutical compositions AFFILIATED MEDICAL RESEARCH Inc 18 Dec 1973 [18 Dec 1972 18 July 1973] 58642/73 Heading A5B Pharmaceutical compositions having analgesic, anti-inflammatory, anti-pyretic and uricosuric activity comprise 5-methyl-1-phenyl-2- (1H)-pyridone, in admixture with one or more of a solid carrier; a flavoured liquid carrier; a flavour; a therapeutic adjuvant; an injectible liquid; a gaseous carrier or diluent; a semisolid carrier for topical administration; or another therapeutic agent. The compositions may be administered orally, rectally parenterally or topically in the form of pulls, tablets, powders, cachets, suppositories, bougies, capsules, pulvules, dragees, aerosols, solutions and suspensions. The compositions may also contain other analgesics e.g. aspirin, sedatives, diuretics, mild stimulants, anti-arryrhnics and tranquilizers.
GB5864273A 1972-12-18 1973-12-18 Pharmaceutical composition Expired GB1458048A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US00315836A US3839346A (en) 1972-12-18 1972-12-18 N-substituted pyridone and general method for preparing pyridones
US38065573A 1973-07-19 1973-07-19

Publications (1)

Publication Number Publication Date
GB1458048A true GB1458048A (en) 1976-12-08

Family

ID=26980095

Family Applications (2)

Application Number Title Priority Date Filing Date
GB4107475A Expired GB1458049A (en) 1972-12-18 1973-12-18 Process for preparing aryl-substituted pyridones
GB5864273A Expired GB1458048A (en) 1972-12-18 1973-12-18 Pharmaceutical composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB4107475A Expired GB1458049A (en) 1972-12-18 1973-12-18 Process for preparing aryl-substituted pyridones

Country Status (6)

Country Link
JP (1) JPS4987677A (en)
DE (2) DE2362958C2 (en)
ES (1) ES421598A1 (en)
FR (1) FR2232316B1 (en)
GB (2) GB1458049A (en)
NL (1) NL7317316A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728013B2 (en) 2005-05-10 2010-06-01 Intermune, Inc. Method of modulating stress-activated protein kinase system
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
ITUB20154832A1 (en) * 2015-10-29 2017-04-29 Procos Spa PROCESS FOR SYNTHESIS OF PYRPHENING
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
JPS5350179A (en) * 1976-10-15 1978-05-08 Rikagaku Kenkyusho Novel 2-pyridone compounds and their preparation
JP4542743B2 (en) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 Solution pharmaceutical composition of pyridone derivatives
MX2007009796A (en) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel containing pirfenidone.
AU2012212269B2 (en) * 2011-01-31 2016-05-19 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (en) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans.
MX346763B (en) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne.
EP3661506A4 (en) * 2017-07-31 2021-04-21 Washington University Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2947755A (en) * 1959-02-05 1960-08-02 Wallace & Tiernan Inc Substituted 1-m-aminophenyl-2-pyridones
US3655897A (en) * 1971-01-25 1972-04-11 Merck & Co Inc Anti-inflammatory agents

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728013B2 (en) 2005-05-10 2010-06-01 Intermune, Inc. Method of modulating stress-activated protein kinase system
US8741936B2 (en) 2005-05-10 2014-06-03 Intermune, Inc. Method of modulating stress-activated protein kinase system
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
US10010536B2 (en) 2005-05-10 2018-07-03 Intermune, Inc. Method of modulating stress-activated protein kinase system
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones
WO2017072216A1 (en) * 2015-10-29 2017-05-04 Procos S.P.A. Process for the synthesis of pirfenidone
US10472325B2 (en) 2015-10-29 2019-11-12 Procos S.P.A. Process for the synthesis of pirfenidone
ITUB20154832A1 (en) * 2015-10-29 2017-04-29 Procos Spa PROCESS FOR SYNTHESIS OF PYRPHENING

Also Published As

Publication number Publication date
ES421598A1 (en) 1977-01-01
NL7317316A (en) 1974-06-20
DE2362958C2 (en) 1984-06-14
JPS4987677A (en) 1974-08-22
FR2232316B1 (en) 1978-03-24
AU6374673A (en) 1975-06-19
FR2232316A1 (en) 1975-01-03
GB1458049A (en) 1976-12-08
DE2366349C2 (en) 1986-03-27
DE2362958A1 (en) 1974-06-27

Similar Documents

Publication Publication Date Title
GB1458048A (en) Pharmaceutical composition
GB1274271A (en) Improvements in or relating to propionic acid derivatives
GB1202148A (en) Pharmaceutical compositions
GB1402691A (en) Composition of 4-biphenyl acetic acid
GB1457546A (en) Pharmaceutical preparations comprising cephalosporin derivatives
GB1442159A (en) Pharmaceutical compositions containing paracetamol
GB1291559A (en) N-(4-chlorocinnamoyl)-4-hydroxypiperidine
GB1535778A (en) Compounds useful in treatment of unipolar depression
GB1359560A (en) Preparation of pyrrylsalicylic acid
GB1352392A (en) Phenylisopropylamine derivatives
FR2308372A2 (en) Medicaments for treatment of cardio-vascular troubles, atheroscleoris - hyperlipemia and hypercholesterolemia contain para-trimethylsilyl-phenoxy-isobutyric acid or para-trimethylsilyl-phenyl-alkanoic acids
GB911482A (en) Pharmaceutical tablets comprising a synergistic combination including salts of ª--phenoxyethyl penicillin
GB1217138A (en) Pharmaceutical compositions based on derivatives of benzimidazole
GB1429977A (en) Diuretic composition
IE35419L (en) Pharmaceutical composition containing cyclobenzaprine
GB1341484A (en) Pharmaceutical compositions
GB1518621A (en) Analgesic composition
SE329398B (en)
GB1280244A (en) Serum triglyceride-lowering compositions
GB1021070A (en) A new triazolone and a process for its preparation
GB1390091A (en) 4-4-biphenylyl-butyric acid derivatives
GB1316006A (en) Pharmaceutically active chemical compound and an antitumourigenic preparation containing same
GB1454390A (en) Nasal decongestants
JPS57179118A (en) Antitumor agent
GB1159272A (en) 1,5-Disubstituted Barbituric Acid Derivatives and process for the manufacture thereof

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee